ST3056

ST3056 is an atypical retinoid and a derivative of the synthetic retinoid ST1926 (a fenretinide analog), characterized by a scaffold containing carboxylic or hydroxamic acid functions. Developed by Sigma-Tau, it exhibits potent proapoptotic and anti-proliferative activity against cancer cells, notably the IGROV-1 ovarian cancer cell line. Its mechanism of action involves the deregulation of calcium homeostasis, induction of oxidative stress, and modulation of specific nuclear proteins, including Far upstream element (FUSE) binding protein 1 (FUBP1) and DNA-binding protein B (YBX1). Unlike classical retinoids, these atypical analogs often induce apoptosis through pathways that are independent of the retinoic acid receptor (RAR).